Skip to main content
Article
The state and consequences of dermatology drug prices in the United States
University of Massachusetts Medical School Faculty Publications
  • Joerg Albrecht, Rush Medical College
  • Mary E. Maloney, University of Massachusetts Medical School
  • Bruce Alan Brod, University of Pennsylvania
UMMS Affiliation
Division of Dermatology, Department of Medicine
Date
9-1-2016
Document Type
Editorial
Abstract

In 2014, Medicare expenditures increased 12%, the largest increase reported since 2002, resulting in major concerns by both patients and physicians. Although costs are rising for both specialty drugs and generic medications,out-of-pocket costs, restrictive formularies,and health plan bureaucracies are limiting patients' access to necessary medications. In response, the Regulatory Policy Committee of the American Academy of Dermatology (AAD)/Association (AAD/A) convened a Task Force on Drug Pricing and Transparency. This editorial summarizes the issues addressed by the task force along with relevant AAD/A policy.

Rights and Permissions
Citation: J Am Acad Dermatol. 2016 Sep;75(3):603-5. doi: 10.1016/j.jaad.2016.03.053. Epub 2016 Jul 13. Link to article on publisher's site
Comments

Full author list omitted for brevity. For full list of authors see article.

Related Resources
Link to Article in PubMed
Keywords
  • coinsurances,
  • drug pricing,
  • formulary tiering,
  • generic drugs,
  • out-of-pocket costs,
  • pharmacy benefit managers,
  • prior authorizations
PubMed ID
27423978
Citation Information
Joerg Albrecht, Mary E. Maloney and Bruce Alan Brod. "The state and consequences of dermatology drug prices in the United States" Vol. 75 Iss. 3 (2016) ISSN: 0190-9622 (Linking)
Available at: http://works.bepress.com/mary_maloney/56/